miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 3, 2026

Stock market today: Dow, Nasdaq, S&P 500 sink as tech falters amid flood of earnings

View original at finance.yahoo.com
Stock market today: Dow, Nasdaq, S&P 500 sink as tech falters amid flood of earnings US stocks sank on Tuesday as investors digested a wave of tech-focused earnings, while precious metals jumped to continue their wild ride and a partial government shutdown neared an end…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Received ERCOT approval for additional 830 MW of power capacity, bringing Helios total to 1.6 gigawatts

    80% confidence
  • Sales drop attributed to continued volume penetration from GLP-1 treatments, intensifying competition, and negative impacts from semaglutide patent expiry

    80% confidence
  • Q4 loss reflects depreciation of digital asset prices and softer macro environment with lower industry trading volumes

    80% confidence
  • Jensen Huang downplayed the $100 billion investment plan with OpenAI

    80% confidence
  • A global rush to secure memory chips for AI is powering renewed surge in South Korean equities

    80% confidence
  • Due to partial government shutdown, BLS will suspend data collection, processing, and dissemination

    80% confidence
  • Silver's transformation from record rally to brutal rout has left traders stunned, battering retail investors

    80% confidence
  • Galaxy Digital remains on track to deliver 133MW of critical IT load to CoreWeave in first half of 2026

    80% confidence
  • Digital assets trading volumes declined by approximately 40% quarter-on-quarter

    80% confidence
  • Darren Woods called Venezuela 'uninvestable' in its current state

    80% confidence
  • US sales impact due to current prescription trends for injectable GLP-1 portfolio, intensifying competition, and reduced obesity medication coverage in Medicaid

    80% confidence
  • Piper Sandler raised Walmart price target to $130 on the company's apparel strength

    80% confidence
  • 2026 sales will likely decline by 5% to 13% as Ozempic and Wegovy face stiffer competition

    80% confidence
  • Bernstein raised SanDisk price target to $1,000 from $580 and maintained Outperform rating

    80% confidence
  • The structural shortage in memory chips makes continued growth of Samsung and SK Hynix inevitable

    80% confidence
  • Throughout 2025, NXP executed effectively despite challenging first half, maintaining operational discipline

    80% confidence
  • Walmart could benefit from tax refund provisions in the One Big Beautiful Bill Act

    80% confidence
  • Thomas Massie was the only Republican to vote no on procedural vote

    80% confidence

Citado en estos reportajes de Via News

Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
Stock market today: Dow, Nasdaq, S&P 500 sink as tech falters amid flood of earnings — Source | Via News | es.VIA.NEWS